Two parents in Alabama are alleging Zofran caused their daughter's heart defects.In one of the newest Zofran lawsuits, parents from Alabama claim their child's birth defect occurred because the mother took Zofran during her pregnancy. Zofran litigation continues to grow, with over 60 lawsuits filed against GlaxoSmithKline. The latest lawsuit, filed in the United States District Court Northern District of Alabama Southern Division under case number 2:15-cv-01552-TMP, alleges that a child’s birth defects were caused by the drug Zofran.
The FDA’s Approval Of ZofranThe U.S. Food and Drug Administration approved Zofran for the treatment of nausea and vomiting, but only for patients who were undergoing radiation and chemotherapy treatments, or patients who were nauseous after anesthesia. The drug was never approved to be prescribed to pregnant women experiencing morning sickness.
GSK’s Marketing DecisionGSK proceeded to market the drug as a treatment for morning sickness without FDA approval. Doctors around the country prescribed the drug to countless women. Since they first began their marketing campaign, GSK has allegedly received over 200 reports of children born with birth defects to women who took Zofran during their pregnancy.
The Alabama ComplaintThe complaint alleges that, because the mother of the child in question took Zofran during her pregnancy, her daughter was born with cardiac defects. The child had to undergo life-saving open heart surgery at just 8 months of age, and her doctors believe that further surgical correction will be required.
Her parents have stated that had they known about the risks associated with using Zofran, the mother would have never taken the drug while pregnant. The lawsuit states that “As a direct and proximate result of GSK’s conduct, the plaintiffs and their daughter have suffered and incurred harm including severe and permanent pain and suffering, mental anguish, medical expenses, and other economic and noneconomic damages, and will require more constant and continuous medical monitoring and treatment than had they not been exposed to the drug.”